Gastromed Kralisz Romatowski Stachurska Sp. j.
- Address
- Ul. Wiosenna 12/1, 15-322 Bialystok, Poland
Gastromed Kralisz Romatowski Stachurska Sp. j. - Advanced Gastroenterology Research Center
Gastromed Kralisz Romatowski Stachurska Sp. j. is a specialized gastroenterology research facility with extensive expertise in investigating inflammatory bowel diseases and upper gastrointestinal disorders. The center demonstrates particular strength in conducting Phase 3 clinical trials evaluating novel biologic therapies and emerging treatment modalities for complex gastrointestinal conditions.
- Crohn's Disease research across multiple phenotypes, including moderately to severely active disease, fistulizing perianal presentations, and fibrostenotic complications
- Ulcerative Colitis treatment trials focusing on moderate to severe disease activity and clinical remission endpoints
- Gastroesophageal Reflux Disease (GERD) and erosive esophagitis therapeutic investigations
- Advanced biologic therapies including interleukin inhibitors and novel immunomodulatory agents
The research center has established itself as a key contributor to international multicenter trials, evaluating cutting-edge therapies such as guselkumab, afimkibart, and other targeted biologics. Their comprehensive approach encompasses both induction and maintenance therapy studies, with particular emphasis on addressing difficult-to-treat complications such as perianal fistulizing disease and intestinal strictures. The facility's participation in pivotal registration trials demonstrates their commitment to advancing evidence-based treatment options for patients with debilitating gastrointestinal conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1F. Hoffmann-La Roche AG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gastromed Kralisz Romatowski Stachurska Sp. j.
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2a, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AGMB-129 in Patients with Fibrostenotic Crohn’s Disease | Agomab Spain S.L.U. | Phase II | Not Recruiting | Nov 2023 | Jun 2026 |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Guselkumab | 3 | Unknown | 2019-10-19 | 2023-02-21 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.